^
Association details:
| Biomarker: | CDKN2A R58X |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Head and Neck Squamous Cell Carcinoma Models for Combined Targeted Therapy Approaches
Published date:
05/18/2022
Excerpt:
This study aimed to refine combined targeted approaches on well-characterized, low-passage tumor models. Upon in vivo xenografting in immunodeficient mice, three cell lines from locally advanced or metastatic HNSCC were established….One cell line (HNSCC48 P0 M1) was sensitive to abemaciclib. Here, Cyto-FISH revealed a partial CDKN2a deletion, which resulted from a R58* mutation.
DOI:
10.3390/cancers14102484
